However, marked biochemical disparities were seen in laboratory investigations, with the HCV-HCC cohort demonstrating significantly elevated liver injury markers, including AST, ALT, and total bilirubin, in comparison to both controls and HCV patients (p < 0.001). The gene discussed is GPT; the disease is hepatocellular carcinoma.